Overdiagnosis or early detection? The controversy of melanoma in situ | 40 min 1

As melanoma in situ diagnoses rise, concerns about overdiagnosis are growing — with real implications for patients, clinicians and the health system.

In this episode of our podcast Melanoma Insights for Professionals, experts from dermatology, pathology, psychology and research come together to explore the drivers of overdiagnosis, the psychological impact of an MIS label, and the role of emerging diagnostic tools and data.

This podcast is suitable for multidisciplinary specialist, primary care physicians and other healthcare professionals.

A Statement of Completion will be provided for your CPD records. Please click FINISH after listening to the podcast.

SPEAKERS
Dr Peter Ferguson
Pathologist, Royal Prince Alfred Hospital and Melanoma Institute Australia
Declaration of Interest



Dr Christoph Sinz
Confocal Microscopy Dermatologist, Melanoma Institute Australia
Declaration of Interest



Claire Gore
Senior Clinical Psychologist, Melanoma Institute Australia
Declaration of Interest



Dr Ismael Vergara
Senior Computational Biologist, Melanoma Institute Australia | Adjunct Senior Lecturer, The University of Sydney
Declaration of Interest




HOST
Danielle Fischer
Education Program Manager, Melanoma Institute Australia
Declaration of Interest




RESOURCES

• MIA’s Patient Guides (e.g. Your Guide to Melanoma In-Situ)
• MIA’s Patient Fact Sheets (e.g. Scanxiety)

• Bjørch MF, Gram EG, Brodersen JB Overdiagnosis in malignant melanoma: a scoping review BMJ Evidence-Based Medicine 2024;29:17-28.
• Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: Can thickness differentials reveal the key drivers? Ann Cancer Epidemiol 2020;4:11
• Daniel Lindsay, Katy J L Bell, Catherine M Olsen, David C Whiteman, Thanya Pathirana, Louisa G Collins, Estimating the magnitude and healthcare costs of melanoma in situand thin invasive melanoma overdiagnosis in Australia British Journal of Dermatology, 2024;191(6): 906–913,
• Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol.2023;159(7):703–710.

MIA’s Education Program is proudly supported through unrestricted educational grants from:        

• Module1.1
  Overdiagnosis or early detection? The controversy of melanoma in situ | 40 min
  40 min